Citations

Showing 10 of 108104 citations.

A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).
Barry, William T., Wenham, Robert M. , Hendrickson, Andrea E. Wahner , Armstrong, Deborah K. , Chan, Nancy , Lee, Jung‐Min , Penson, Richard T. , Cristea, Mihaela , Abbruzzese, James L. , Matsuo, Koji , Olawaiye, Alexander , Farooq, Sarah , Kohn, Elise C. , Matulonis, Ursula A. , Liu, Joyce F. , Cohn, David E. , Swisher, Elizabeth M. , Van Allen, Eliezer M , Shapiro, Geoffrey I. , Ivy, S. Percy

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5519-5519

10.1200/jco.2018.36.15_suppl.5519 Get It

Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial.
Liu, Glenn , Jarrard, David F. , García, Jorge A. , Hussain, Maha , Eisenberger, Mario A. , Hahn, Noah M. , DiPaola, Robert S. , Harshman, Lauren C. , Hussain, Maha H A , Bryce, Alan H. , Chen, Yu‐Hui , Carducci, Michael A. , Dreicer, Robert , Kohli, Manish , Plimack, Elizabeth R. , Vogelzang, Nicholas J. , Picus, Joel , Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 5046-5046

10.1200/jco.2018.36.15_suppl.5046 Get It

FIERCE-21: Phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC).
Arriaga, Yull , Milowsky, Matthew I. , Currie, Graeme, Abella, Steve, Pal, Sumanta K. , Bellmunt, Joaquim , Picus, Joel , Kohli, Manish

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4534-4534

10.1200/jco.2018.36.15_suppl.4534 Get It

A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma.
Vaishampayan, Ulka N. , Matrana, Marc , Zurita, Amado J. , Keam, Bhumsuk , Sundararajan, Srinath , Mowat, Rex B., Dudek, Arkadiusz Z. , Gan, Lu , Vaishampayan, Ulka , McDermott, David F. , Rha, Sun Young , Ho, Thai H. , Lee, Jae‐Lyun , Joseph, Richard W. , Ali, Sarah, Stadler, Walter M. , Haas, Naomi B , Park, Se Hoon , Picus, Joel , Zakharia, Yousef , Atkins, Michael B. , Dudek, Arkadiusz Z

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4510-4510

10.1200/jco.2018.36.15_suppl.4510 Get It

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).
Hu, James , Srinivas, Sandy, Costello, Brian A. , Milowsky, Matthew I. , Bromberg, Maria , Nolan, Patrick , Dorff, Tanya B. , Reuter, Victor E. , Bajorin, Dean F. , Feldman, Darren Richard , Stadler, Walter M. , Appleman, Leonard J. , Patil, Sujata N , Al-Ahmadie, Hikmat A , Funt, Samuel A. , Bosl, George J. , Quinn, David I , Motzer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4508-4508

10.1200/jco.2018.36.15_suppl.4508 Get It

A phase 1 safety study of SBP-101, a polyamine metabolic inhibitor, for pancreatic ductal adenocarcinoma (PDA).
Kotasek, Dusan , Borazanci, Erkut , Smith, Sheri , Shah, Ajit , Walker, Michael J. , Cullen, Michael, Gagnon, Suzanne , Borazanci, Erkut , Tebbutt, Niall C. , Borad, Mitesh J. , Cullen, Michael T.

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16231-e16231

10.1200/jco.2018.36.15_suppl.e16231 Get It

Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC).
McGarrah, Patrick W. , Leventakos, Konstantinos , Hobday, Timothy J. , Molina, Julian R. , Finnes, Heidi D. , Hálfdánarson, Þorvarður R. , Westin, Gustavo Figueiredo Marcondes, Halfdanarson, Thorvardur R , McGarrah, Patrick

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: e16162-e16162

10.1200/jco.2018.36.15_suppl.e16162 Get It

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.
Oh, Do‐Youn , Al‐Batran, Salah‐Eddin , Iqbal, Syma , Kim, Kyu‐pyo , Lacy, Jill , Manji, Gulam A. , Rahma, Osama E. , Yoon, Harry H. , Kwan, Antonia , He, Xian , Barak, Hila, Sayyed, Pakeeza, Zhang, Xiaosong , Cha, Edward , Chung, Hyun Cheol , Hollebecque, Antoine , O’Reilly, Eileen M. , Wang, Jun , Bekaii‐Saab, Tanios

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS4134-TPS4134

10.1200/jco.2018.36.15_suppl.tps4134 Get It

A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy (PD) for patients with resectable pancreatic ductal adenocarcinoma (PDAC): ACOSOG Z5041 trial (Alliance).
Wolff, Robert A. , Kindler, Hedy L. , Evans, Douglas B. , Misdraji, Joseph , Tamm, Eric P. , Sahani, Dushyant V., Moore, Malcolm J. , Newman, Elliot , Merchant, Nipun B. , Goff, Laura W. , Pisters, Peter W. T., Posner, Mitchell C. , (Alliance), ACOSOG, Wei, Alice C. , Ou, Fang‐Shu , Shi, Qian , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Deshpande, Vikram , Berlin, Jordan D. , (Alliance), ACOSOG

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4112-4112

10.1200/jco.2018.36.15_suppl.4112 Get It

A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC).
Dean, Andrew , Ramanathan, Ramesh K., Mody, Kabir , Belanger, Bruce , Jong, Floris A. de, Braun, Stephan , Wainberg, Zev A. , Boland, Patrick M. , Zhang, Bin

Mayo Clinic

Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: 4111-4111

10.1200/jco.2018.36.15_suppl.4111 Get It